Sees FY24 product revenues, net $138.0M-$158.0M; and adjusted operating expenses $108.0M-$116.0M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRTX:
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- Heron Therapeutics Inc (HRTX) Q4 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics Gains FDA Nod for ZYNRELEF® Expansion
